Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia ...Middle East

PR Newswire - News
VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for treatment of FTD(GRN) Data demonstrate excellent safety, tolerability profile, dose-proportionality and target engagement with elevations in progranulin in both plasma and CNS CTA filed for Phase IIa...

Hence then, the article about vesper bio announces successful phase i study for potentially disease modifying treatment for frontotemporal dementia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia )

Apple Storegoogle play

Last updated :

Also on site :